Saturday 18 August 2018
Contact US    |    Archive
Reuters
3 months ago

Evolus investors frown as FDA declines to approve Botox rival

(Reuters) - U.S. health regulators on Wednesday declined to approve Evolus Inc s rival product to Allergan Plc s Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as

Read on the original site


هذه الصفحة هي مجرد قاریء تلقائي للأخبار باستخدام خدمة الـ RSS و بأن نشر هذه الأخبار هنا لاتعني تأییدها علی الإطلاق.
Hashtags:   

Evolus

 | 

investors

 | 

frown

 | 

FDA

 | 

declines

 | 

approve

 | 

Botox

 | 

rival

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)